GlassScriptPhysician profile
Amber S Riley
NPI 1841538030
$1,622.56
in general payments reported to CMS, 2019-2025
21 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $182 · 2023: $280 · 2024: $418 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.01 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lundbeck LLC | $234.11 | 2022-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $191.77 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $126.53 | 2021-2025 | |
| Novo Nordisk INC | $126.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $68.65 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.34 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.90 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $50.20 | 2022-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $37.00 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Ironshore Pharmaceuticals INC. | $33.19 | 2024 | |
| Horizon Therapeutics Plc | $32.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.53 | 2025 | |
| Tris Pharma INC | $21.32 | 2023 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.11 | 2024 | Caplyta |
| Abbott Laboratories | $17.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.61 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.12 | 2021 | |
| Medtronic, INC. | $13.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.